Literature DB >> 26429274

Paddle-based rotating-shield brachytherapy.

Yunlong Liu1, Ryan T Flynn2, Yusung Kim2, Hossein Dadkhah3, Sudershan K Bhatia2, John M Buatti2, Weiyu Xu1, Xiaodong Wu4.   

Abstract

PURPOSE: The authors present a novel paddle-based rotating-shield brachytherapy (P-RSBT) method, whose radiation-attenuating shields are formed with a multileaf collimator (MLC), consisting of retractable paddles, to achieve intensity modulation in high-dose-rate brachytherapy.
METHODS: Five cervical cancer patients using an intrauterine tandem applicator were considered to assess the potential benefit of the P-RSBT method. The P-RSBT source used was a 50 kV electronic brachytherapy source (Xoft Axxent™). The paddles can be retracted independently to form multiple emission windows around the source for radiation delivery. The MLC was assumed to be rotatable. P-RSBT treatment plans were generated using the asymmetric dose-volume optimization with smoothness control method [Liu et al., Med. Phys. 41(11), 111709 (11pp.) (2014)] with a delivery time constraint, different paddle sizes, and different rotation strides. The number of treatment fractions (fx) was assumed to be five. As brachytherapy is delivered as a boost for cervical cancer, the dose distribution for each case includes the dose from external beam radiotherapy as well, which is 45 Gy in 25 fx. The high-risk clinical target volume (HR-CTV) doses were escalated until the minimum dose to the hottest 2 cm(3) (D(2cm(3)) of either the rectum, sigmoid colon, or bladder reached their tolerance doses of 75, 75, and 90 Gy3, respectively, expressed as equivalent doses in 2 Gy fractions (EQD2 with α/β = 3 Gy).
RESULTS: P-RSBT outperformed the two other RSBT delivery techniques, single-shield RSBT (S-RSBT) and dynamic-shield RSBT (D-RSBT), with a properly selected paddle size. If the paddle size was angled at 60°, the average D90 increases for the delivery plans by P-RSBT on the five cases, compared to S-RSBT, were 2.2, 8.3, 12.6, 11.9, and 9.1 Gy10, respectively, with delivery times of 10, 15, 20, 25, and 30 min/fx. The increases in HR-CTV D90, compared to D-RSBT, were 16.6, 12.9, 7.2, 3.7, and 1.7 Gy10, respectively. P-RSBT HR-CTV D90-values were insensitive to the paddle size for paddles angled at less than 60°. Increasing the paddle angle from 5° to 60° resulted in only a 0.6 Gy10 decrease in HR-CTV D90 on average for five cases when the delivery times were set to 15 min/fx. The HR-CTV D90 decreased to 2.5 and 11.9 Gy10 with paddle angles of 90° and 120°, respectively.
CONCLUSIONS: P-RSBT produces treatment plans that are dosimetrically and temporally superior to those of S-RSBT and D-RSBT, although P-RSBT systems may be more mechanically challenging to develop than S-RSBT or D-RSBT. A P-RSBT implementation with 4-6 shield paddles would be sufficient to outperform S-RSBT and D-RSBT if delivery times are constrained to less than 15 min/fx.

Entities:  

Mesh:

Year:  2015        PMID: 26429274      PMCID: PMC5148177          DOI: 10.1118/1.4930807

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  18 in total

1.  American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles.

Authors:  Akila N Viswanathan; Bruce Thomadsen
Journal:  Brachytherapy       Date:  2012 Jan-Feb       Impact factor: 2.362

2.  The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer: clinical feasibility and preliminary results.

Authors:  Johannes C A Dimopoulos; Christian Kirisits; Primoz Petric; Petra Georg; Stefan Lang; Daniel Berger; Richard Pötter
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-07-12       Impact factor: 7.038

3.  Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology.

Authors:  Richard Pötter; Christine Haie-Meder; Erik Van Limbergen; Isabelle Barillot; Marisol De Brabandere; Johannes Dimopoulos; Isabelle Dumas; Beth Erickson; Stefan Lang; An Nulens; Peter Petrow; Jason Rownd; Christian Kirisits
Journal:  Radiother Oncol       Date:  2006-01-05       Impact factor: 6.280

4.  The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer: design, application, treatment planning, and dosimetric results.

Authors:  Christian Kirisits; Stefan Lang; Johannes Dimopoulos; Daniel Berger; Dietmar Georg; Richard Pötter
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-06-01       Impact factor: 7.038

5.  MRI-guided treatment-planning optimisation in intracavitary or combined intracavitary/interstitial PDR brachytherapy using tandem ovoid applicators in locally advanced cervical cancer.

Authors:  Ina M Jürgenliemk-Schulz; Robbert J H A Tersteeg; Judith M Roesink; Stefan Bijmolt; Christel N Nomden; Marinus A Moerland; Astrid A C de Leeuw
Journal:  Radiother Oncol       Date:  2009-09-11       Impact factor: 6.280

6.  Asymmetric dose-volume optimization with smoothness control for rotating-shield brachytherapy.

Authors:  Yunlong Liu; Ryan T Flynn; Yusung Kim; Xiaodong Wu
Journal:  Med Phys       Date:  2014-11       Impact factor: 4.071

7.  From point A to the sculpted pear: MR image guidance significantly improves tumour dose and sparing of organs at risk in brachytherapy of cervical cancer.

Authors:  Kari Tanderup; Søren Kynde Nielsen; Gitte-Bettina Nyvang; Erik Morre Pedersen; Lisbeth Røhl; Torben Aagaard; Lars Fokdal; Jacob Christian Lindegaard
Journal:  Radiother Oncol       Date:  2010-02       Impact factor: 6.280

8.  Dynamic rotating-shield brachytherapy.

Authors:  Yunlong Liu; Ryan T Flynn; Yusung Kim; Wenjun Yang; Xiaodong Wu
Journal:  Med Phys       Date:  2013-12       Impact factor: 4.071

9.  Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer.

Authors:  Richard Pötter; Johannes Dimopoulos; Petra Georg; Stefan Lang; Claudia Waldhäusl; Natascha Wachter-Gerstner; Hajo Weitmann; Alexander Reinthaller; Tomas Hendrik Knocke; Stefan Wachter; Christian Kirisits
Journal:  Radiother Oncol       Date:  2007-05       Impact factor: 6.280

10.  Rapid emission angle selection for rotating-shield brachytherapy.

Authors:  Yunlong Liu; Ryan T Flynn; Wenjun Yang; Yusung Kim; Sudershan K Bhatia; Wenqing Sun; Xiaodong Wu
Journal:  Med Phys       Date:  2013-05       Impact factor: 4.071

View more
  6 in total

1.  Needle-free cervical cancer treatment using helical multishield intracavitary rotating shield brachytherapy with the 169 Yb Isotope.

Authors:  Karolyn M Hopfensperger; Quentin Adams; Yusung Kim; Xiaodong Wu; Weiyu Xu; Kaustubh Patwardhan; Bounnak Thammavong; Joseph Caster; Ryan T Flynn
Journal:  Med Phys       Date:  2020-03-13       Impact factor: 4.071

2.  Multisource Rotating Shield Brachytherapy Apparatus for Prostate Cancer.

Authors:  Hossein Dadkhah; Karolyn M Hopfensperger; Yusung Kim; Xiaodong Wu; Ryan T Flynn
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-06-20       Impact factor: 7.038

3.  Preliminary Monte Carlo Investigation of Using Ir-192 as the Source for Real Time Imaging Purpose.

Authors:  Chengyu Shi; Brian Wang
Journal:  Int J Med Phys Clin Eng Radiat Oncol       Date:  2017-01-12

4.  Efficient 169 Yb high-dose-rate brachytherapy source production using reactivation.

Authors:  Ryan T Flynn; Quentin E Adams; Karolyn M Hopfensperger; Xiaodong Wu; Weiyu Xu; Yusung Kim
Journal:  Med Phys       Date:  2019-05-27       Impact factor: 4.071

Review 5.  Evolution of Brachytherapy Applicators for the Treatment of Cervical Cancer.

Authors:  Ankur Mourya; Lalit Mohan Aggarwal; Sunil Choudhary
Journal:  J Med Phys       Date:  2021-12-31

6.  Intensity Modulated High Dose Rate (HDR) Brachytherapy Using Patient Specific 3D Metal Printed Applicators: Proof of Concept.

Authors:  James J Sohn; Mitchell Polizzi; Sang-Won Kang; Woo-Hyeong Ko; Yong-Hyun Cho; Keun-Yong Eom; Jin-Beom Chung
Journal:  Front Oncol       Date:  2022-02-10       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.